Get all premium features to the best stock analysis tool

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Strong organic revenue growth1 in 2025 of 8% driven by all operating segments Driven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3% Reported operating income grew by 31%, reported net income3 by 82% Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback program Dividend of EUR 1.49 (+3%) planned to be proposed FY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwinds BAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains. Over the past three years, we built a stronger and more resilient company, meeting all key financial and strategic aspects of the mid-term outlook that we had set for 2025.

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

The second tranche of the share buyback is expected to be executed by May 8, 2026 The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally planned BAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion.

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer As part of a planned transition Franklin W. Maddux will retire by year end BAD HOMBURG, Germany , Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026.

Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025

Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7% Reported operating income grew by 3%, reported net income3 by 29% Net leverage ratio further improved to 2.6x, in parallel to share buyback and Value-Based Care investments FY 2025 outlook confirmed BAD HOMBURG, Germany, Nov. 4, 2025 /PRNewswire/ -- "In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income2 growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress.